Log on / register
Feedback | Support | My details
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].
FIELD Study Investigators
Cardiovasc Diabetol 2004 Dec 1, 3:9
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.
36%36%


 Original investigation
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
The FIELD Study Investigators
Cardiovascular Diabetology 2005, 4:13 (22 August 2005)
[Full text] [PubMed Central] [PubMed] [Related articles]
2.
36%36%


 Editorial
Statins research unfinished saga: desirability versus feasibility
Fisman EZ, Adler Y, Tenenbaum A
Cardiovascular Diabetology 2005, 4:8 (7 June 2005)
[Full text] [PubMed Central] [PubMed] [Related articles] [Cited on BioMed Central]
3.
36%36%


 Editorial
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
Tenenbaum A, Fisman EZ
Cardiovascular Diabetology 2004, 3:10 (1 December 2004)
[Full text] [PubMed Central] [PubMed] [Related articles] [Cited on BioMed Central]
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2008 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.